Connect with us


Lion’s mane: what is it and why should I include it in my daily routine? 

In this article, MyFunghi explores the benefits of the lion’s mane mushroom as a functional supplement to daily routines.



Lion’s mane: what is it and why should I include it in my daily routine? 

The lion’s mane mushroom has a long and complex history of being used as a supplement as part of a healthy diet. 

Ancient civilisations were aware of the healing and wellbeing effects of lion’s mane and successfully harnessed them using a variety of ways including powders, tonics and tinctures. 

Also known as Hericium erinaceus, the mushroom gets its nickname from the long, flowing, hair-like structures that grow from it, giving it the distinctive look of a shaggy lion’s mane. It can grow up the size of a football and is often found growing on dying or dead trees.  

So how can his funny-looking fungus be beneficial to us? 

Current research on its benefits show very promising results. Positively affecting every major organ in the human body, lion’s mane really is the miracle mushroom. Millions of people already use this fungus as part of their daily routine, so why should you? 

Benefits of lion’s mane
Increased brain function and memory

This is probably one of the most well-known benefits. Known as a  nootropic, which is a substance that can boost memory and mental capacity, it is thought to help some people improve their focus, memory and clear brain fog. 

study conducted with older adults showed that 3g daily caused a significant improvement in cognitive function and ability. There is also some research showing it can help repair and heal damage or trauma that is sustained to the brain.

Inflammation Reduction

Lion’s Mane has been shown to have strong anti-inflammatory properties. Recent studies with animals have shown that lion’s mane can effectively reduce chronic inflammation with long-term use. Inflammation can occur as a symptom of chronic illness or disease. Lion’s mane can offer relief to chronic inflammation and particularly help with inflamed joints due to arthritis as well as chronic bowel inflammation due to IBS, IBD and other such digestive diseases. 

See also  Salvinorin A to be researched for treatment of mental health conditions

Heart health

Recent research has shown that lion’s mane effectively reduces cholesterol which can reduce the risk of heart disease in later life.

Furthermore, studies have shown lion’s mane reduces the oxidation of cholesterol in the blood. Oxidized cholesterol molecules tend to attach to the walls of arteries of the heart.

This causes the arteries to harden, increasing the risk of heart attack and stroke. Therefore, reduced oxidisation of cholesterol in the bloodstream is hugely beneficial for maintaining a healthy heart. 

As if this wonder mushroom couldn’t do anymore for the heart, the mushroom also contains a compound called hericenone B, which can decrease the rate of blood clotting further lowering the risk of heart attack or stroke.

Diabetes symptom relief

Diabetes occurs when an individual can no longer control blood sugar levels effectively and so the blood sugar levels in that individual remains at an elevated level. If left untreated this can result in severe complications from blindness, kidney disease, loss of limbs and even death. 

Recent research has shown that the mushroom has significant promise in the treatment of high blood sugar levels, as several animal studies have shown that it can cause significantly lower blood sugar levels. 

Lion’s mane lowers blood sugars by blocking the activity of the enzyme alpha-glucosidase, which breaks down carbs in the small intestine. When this enzyme is blocked, the body is unable to digest and absorb carbs as effectively, which results in lower blood sugar levels.

So with all these benefits, are there any side effects when taking lion’s mane?

No, studies have shown that lion’s mane is very safe to take with no adverse effects.

The exception to this is if you have an allergy or sensitivity to mushrooms. Lion’s mane is a variety of mushroom and if you have an allergy or sensitivity to mushrooms, we advise you contact your doctor before consuming. 

See also  Mindcure to help drive adoption of digital therapeutics     

Want to try and start benefiting from this miracle mushroom? 

Head over to our organic oil. Here at our lion’s mane tincture is 8:1 concentrated and equivalent to 12,000mg per product, making it the most potent Lion’s Mane extract in the world.

You can find our lion’s mane by clicking here.

Psychedelic Health is not responsible for the contents of this article.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published.


Patient approved to receive psilocybin therapy for MDD

Braxia Scientific will deliver the therapy through Health Canada’s Special Access Program (SAP).



Patient approved to receive psilocybin therapy for MDD

Braxia Scientific has received approval from Health Canada to provide psilocybin-assisted psychotherapy for a patient with Major Depressive Disorder (MDD) in Ontario.

The psilocybin-assisted therapy will be delivered through Braxia’s wholly owned subsidiary Canadian Rapid Treatment Centre of Excellence (CRTCE).

The approval is Braxia‘s first psilocybin-assisted therapy treatment using Health Canada’s SAP, however, the company was the first to receive Health Canada approval for a multi-dose psilocybin-assisted therapy clinical trial in July 2021.

See also  Health Canada approves low-dose psilocybin mental health clinical trial  

Chief Medical and Scientific Officer at Braxia Scientific, Dr Joshua Rosenblat, commented: “Being among the first to begin delivering psilocybin-assisted therapy treatments in Canada last year through our clinical trial, we have developed and optimised the infrastructure, including rigorous training for our therapists through our Braxia Institute, to provide a positive patient experience while optimising outcomes.”

“To our knowledge, this is the first Health Canada SAP approval for psilocybin-assisted therapy for a person with Major Depressive Disorder in Ontario. 

“My patient and I are extremely grateful for this opportunity to access this promising treatment. Health Canada was very responsive to this request, promptly providing the Letter of Authorization. 

“This rapid approval stands in contrast to the previously required Section 56 exemptions that could take years to fully process. Allowing use of the SAP will be incredibly beneficial for patients in need of this treatment that are unable to receive it through psychedelic clinical trials.”

Chairman and CEO of Braxia Scientific, Dr Roger McIntyre, commented: “Since opening our first clinic in 2018, in Toronto, Canada, our focus has been on creating a true centre of excellence for people living and suffering with depression to gain access to the most effective treatments. 

“Our ability to deliver psilocybin-assisted therapy is an important step in our journey to achieving our vision of finding a cure for depression.

“The experience of our therapists who have already delivered this novel treatment in multiple doses to multiple patients in our ongoing psilocybin trial, combined with data we’ve collected to date and expect to read out in the coming weeks, provides an excellent opportunity for new applicants to receive access to the most advanced clinical protocols and care to achieve best outcomes in this field. 

“In addition to providing access to innovative treatments for depression, Braxia Scientific is a   leader in comprehensive research, development and best-practices implementation of psilocybin, ketamine and related agents.”

Continue Reading


Numinus receives Health Canada SAP approval for psilocybin therapy

Numinus says it hopes the approval is the beginning for Canadian patients to obtain access to mental health care through psychedelic medicine.



Numinus receives Health Canada SAP approval for psilocybin therapy

Health Canada has granted approval to Numinus’ application to complete psychedelic-assisted therapy using psilocybin to treat an applicant with treatment-resistant depression.

In January this year, Health Canada amended its Special Access Program (SAP) to include access to psychedelic compounds on a case-by-case basis.

To be considered for the SAP program, an applicant must have a serious or life-threatening condition where conventional treatments have failed, are unsuitable or are not available in Canada.

Recent research has shown that psilocybin-assisted therapy holds promise as a treatment for a number of different mental health disorders such as depression. Numinus, which is focused on advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, put forward an application for its psilocybin therapy to be included on the (SAP).

See also  Extension of MDMA PTSD study to be hosted by Numinus

Founder and CEO of Numinus, Payton Nyquvest, commented: “I am proud that Numinus is working with Health Canada to help Canadians with mental health challenges in ways that were not previously available, including using psilocybin-assisted therapy through Health Canada’s SAP.

”The SAP recognises a growing body of research that has consistently shown the efficacy of psychedelic-assisted psychotherapy to treat a broad range of mental health conditions that are extremely difficult to treat with conventional therapies. 

“We hope that our first psilocybin-assisted therapy treatment is the beginning for more opportunities for Canadian patients to obtain safe access to treatment and care in the mental health sector through psychedelic medicine.”

See also  Health Canada approves low-dose psilocybin mental health clinical trial  

Numinus has confirmed that the treatment will take place at one of its Montreal clinics, consisting of psilocybin-assisted therapy including several preparatory and integration therapy sessions, medical consults and one psilocybin-dosing session. 

All practitioners involved in the treatment have been trained through Numinus’ proprietary psilocybin-assisted therapy protocol and Numinus will partner with Psygen Labs, an approved Health Canada supplier, to provide the synthetic psilocybin to be taken orally during the dosing session.

Dr. Andrew Bui-Nguyen, Numinus’ Québec regional medical director, who completed the application, said: “Numinus has been working with this applicant through other available services over an extended period and we are proud that we can now provide this deeply important treatment. 

“To our knowledge, this is the first Health Canada SAP approval for psilocybin-assisted therapy for someone suffering from treatment-resistant depression in Québec, and the first time our Numinus team will provide this treatment outside of the clinical trial setting.”

As they are approached by treatment-resistant patients who meet this criteria, Numinus-affiliate physicians plan to make additional applications for clients suffering from a range of mental health conditions in BC and Québec.

Continue Reading


Phase III trail of MDMA therapy for PTSD fully enroled

The completion of the MAPS trial enrolment brings the company step closer to making the treatment available for patients.



Phase III trail of MDMA therapy for PTSD fully enroled

The non-profit Multidisciplinary Association of Psychedelic Studies (MAPS) has confirmed it has now fully enroled its Phase III trial of MDMA-assisted therapy for PTSD.

It is currently estimated that more than 300 million people are living with PTSD worldwide, with around 12 million experiencing the condition each year in the US. 

About half of people with PTSD achieve symptom reduction through psychotherapy or pharmaceutical interventions. However, for some, PTSD is a chronic condition resulting in serious comorbidities including anxiety, insomnia, hypertension, depression and substance use disorder.

See also  atai donates to MAPS to support health equity through psychedelics


The MAPS Phase III trial is aiming to help meet the unmet need for treatment in this area, and is expected to take place at 13 sites across the US and Israel. The second, confirmatory Phase III trial of MDMA-assisted therapy for PTSD is now fully enrolled at 13 sites in the United States and Israel.

MAPS’ first Phase III trial indicated that MDMA may be a safe and effective treatment for PTSD resulting from any cause, with 88 per cent of participants demonstrating a clinically significant reduction in PTSD symptoms two months after the last experimental session, with no serious safety signals emerging. 

After negotiating a special protocol agreement with the US Food and Drug Administration (FDA) for the confirmatory trial, MAPP2 was designed to enrol at least 100 participants in order to confirm the efficacy and further investigate the safety of the treatment.

If the MAPP2 study results, available after October 2022, are statistically significant for a reduction in PTSD symptoms and meet the FDA standards for safety, MAPS and MAPS PBC are planning to submit a New Drug Application to the FDA in the first half of 2023.

CEO of MAPS Public Benefit Corporation, Amy Emerson, commented: “For nearly 20 years, MAPS has sponsored innovative, careful research into the potential of MDMA to treat PTSD. 

“MAPS PBC, supported through the dedication of staff, consultants, participants in the studies, and donors, has organised world-class research into a novel treatment for a devastating condition with too few treatment options. 

“Together, we are eagerly awaiting the possibility that our scientific inquiry may be confirmed in this critically important trial scheduled to be completed in October 2022.”

Associate director for Pivotal Programs, Charlotte Harrison, B.A., commented: ”The completion of enrolment brings us one step closer to making this novel treatment available to the many people who were not able to participate and accessible to those who need it most. 

“We are ever grateful for the participants who spent many hours on their healing journeys in this trial and to the therapists, study coordinators, doctors, and MAPS PBC staff who have dedicated their careers to this effort.”


MAPS is implementing Health Equity initiatives to enrol BIPOC and LGBTQIA+ participants improved representation of populations most likely to develop PTSD following exposure to trauma.

MAPS highlights that, among Americans exposed to trauma, people of colour and LGBTQ+ individuals are more likely to develop PTSD, yet less likely to receive a diagnosis or have reasonable access to treatment. 

Research demonstrates that racial and ethnic alignment among healthcare providers and their patients can improve survival, safety and trust for patients. However, marginalised populations are historically underrepresented in clinical research, including in MAPS-sponsored trials. 

Through equity initiatives in therapist training and participant recruitment, participants in MAPP2 are more representative of the population of people living with PTSD.

Continue Reading


Psychedelic Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. We do not provide medical advice or promote the personal use of psychedelic compounds. Please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2021 H&W Media Ltd.